SG10201809464RA - Antibody gene expression-secretion system - Google Patents

Antibody gene expression-secretion system

Info

Publication number
SG10201809464RA
SG10201809464RA SG10201809464RA SG10201809464RA SG10201809464RA SG 10201809464R A SG10201809464R A SG 10201809464RA SG 10201809464R A SG10201809464R A SG 10201809464RA SG 10201809464R A SG10201809464R A SG 10201809464RA SG 10201809464R A SG10201809464R A SG 10201809464RA
Authority
SG
Singapore
Prior art keywords
antibody
terminus
antibody gene
gene expression
secretion system
Prior art date
Application number
SG10201809464RA
Inventor
Shun-Ichiro Taniguchi
Yasuto Akiyama
Takeshi Masaki
Hitomi Shimizu
Original Assignee
Univ Shinshu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Shinshu filed Critical Univ Shinshu
Publication of SG10201809464RA publication Critical patent/SG10201809464RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTIBODY GENE EXPRESSION-SECRETION SYSTEM It is an object of the present invention to provide signal sequence information capable of secreting an antibody to the outside of cells in generation of the antibody by microorganisms of genus Bifidobacterium, and an antibody expression vector capable of secreting an antibody to the outside of cells by utilizing the signal sequence information. As a means for achieving the aforementioned object, there is prepared Bifidobacterium longum, which is transformed with a vector having inserted thereinto a DNA insert comprising the 5'-terminus of an antibody gene linked to the 3'-terminus of a DNA encoding a signal peptide-linker conjugate having a linker linked to the C-terminus of a signal peptide consisting of an amino acid sequence shown in SEQ ID NO: 1. [No Suitable Figure]
SG10201809464RA 2014-05-02 2015-04-17 Antibody gene expression-secretion system SG10201809464RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014095440 2014-05-02

Publications (1)

Publication Number Publication Date
SG10201809464RA true SG10201809464RA (en) 2018-11-29

Family

ID=54358387

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201809464RA SG10201809464RA (en) 2014-05-02 2015-04-17 Antibody gene expression-secretion system
SG11201609108TA SG11201609108TA (en) 2014-05-02 2015-04-17 Antibody gene expression-secretion system

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201609108TA SG11201609108TA (en) 2014-05-02 2015-04-17 Antibody gene expression-secretion system

Country Status (8)

Country Link
US (1) US10344093B2 (en)
EP (1) EP3138907B1 (en)
JP (1) JP6573398B2 (en)
KR (1) KR20160147778A (en)
CN (1) CN106536738B (en)
CA (1) CA2947529C (en)
SG (2) SG10201809464RA (en)
WO (1) WO2015166641A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201704450UA (en) * 2014-12-03 2017-06-29 Anaeropharma Science Inc Coexpression plasmid
WO2017203051A1 (en) * 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
JPWO2019124461A1 (en) * 2017-12-19 2020-12-24 国立大学法人北海道大学 Method for producing antibody fragment multimer molecule, pharmaceutical product, antitumor agent, autoimmune disease therapeutic agent and antibody fragment multimer molecule

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1264885A4 (en) 2000-02-22 2007-02-21 Med & Biological Lab Co Ltd Antibody library
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
JP2006180708A (en) 2003-03-31 2006-07-13 Institute For Antibodies Co Ltd Method for preparation of antibody
JP2010035472A (en) 2008-08-04 2010-02-18 Shizuoka Prefecture Method for screening new cancer antigen-specific antibody gene using sst-rex method
KR101850162B1 (en) * 2010-01-29 2018-04-18 가부시키가이샤 아네로파마·사이엔스 Transformation plasmid
WO2013065869A1 (en) 2011-11-02 2013-05-10 Ajinomoto Co.,Inc. Method for secretory production of protein
SG11201609032WA (en) 2014-05-01 2016-12-29 Anaeropharma Science Inc Heterogeneous polypeptide expression cassette

Also Published As

Publication number Publication date
CN106536738A (en) 2017-03-22
CN106536738B (en) 2019-12-10
US20170218072A1 (en) 2017-08-03
SG11201609108TA (en) 2016-12-29
WO2015166641A1 (en) 2015-11-05
JPWO2015166641A1 (en) 2017-04-20
EP3138907B1 (en) 2020-02-26
EP3138907A1 (en) 2017-03-08
CA2947529C (en) 2022-06-21
EP3138907A4 (en) 2017-11-01
JP6573398B2 (en) 2019-09-11
KR20160147778A (en) 2016-12-23
CA2947529A1 (en) 2015-11-05
US10344093B2 (en) 2019-07-09

Similar Documents

Publication Publication Date Title
NZ704192A (en) Cell-penetrating peptides and uses therof
NZ603813A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
NZ612512A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
MX2012011405A (en) CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.
NZ599259A (en) Mycobacterial vaccines
MY162737A (en) 4-1bb binding molecules
MX2018010616A (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same.
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
NZ609216A (en) Anticancer fusion protein
WO2016130628A8 (en) Griffithsin mutants
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
MX2015007421A (en) Modified coiled coil type proteins having improved properties.
MX2014008028A (en) Anticancer fusion protein.
NZ706884A (en) Fc gamma receptor iib variants
UA115235C2 (en) Bacillus thuringiensis toxin gene axmi335 and methods for its use
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
MX361434B (en) Npp1 fusion proteins.
NZ598932A (en) Identification of antigenic peptides from multiple myeloma cells
SG10201809464RA (en) Antibody gene expression-secretion system
MX2009007261A (en) Foxp3 peptide vaccine.
IN2014DN09963A (en)
NZ600818A (en) Cyclic peptides for the regulation of vectorial ion channels
MX2010005816A (en) Stat3 epitope peptides.
MY151307A (en) Peptides having antimicrobial activity